HBFOTC FILING WATCHBY HONGBO FINANCELIVE WIREOFFICIAL SEC RECORDS · FINRA OTC DAILY LIST
公司公告

Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results

INTERPACE BIOSCIENCES, INC. · IDXG

原披露日期:;精度:秒。

来源:SEC(SEC EDGAR 8-K)。

查看原始披露 ↗

查看已提交的公告附件 ↗

融资准备壳资料工具

原文限定:Interpace is seeking to extend the next-generation sequencing and microRNA technology platforms behind ThyGeNEXT ® and ThyraMIR ® v2 into pancreatic cancer. The program design includes an extensive genomic panel and proprietary microRNA classification aligned with National Comprehensive Cancer Network (NCCN) guidelines. Together, these technologies are intended to provide decision-making support to clinicians, including medical oncologists, for pancreatic cancer detection, classification, and neoadjuvant treatment selection. Analytical validation of the panel design is underway, with clinical validation and utility studies planned across 2026 and 2027, and reimbursement and launch activities to follow. This new product is in development, not yet available for clinical use, and has not been cleared or approved by the U.S. Food and Drug Administration. There can be no assurance that development will be completed on the anticipated timeline or at all, and the Company does not expect the program to contribute revenue in 2026 or 2027.

原文限定:Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

原文限定:Reconciliation of Pro Forma (Unaudited)

原文限定:Reconciliation of Adjusted EBITDA (Unaudited)

标题保留原文的计划、申请、条件、初步结果及否定状态,以原文为准。本站核验来源归属、证券身份及披露时间,不保证公司陈述或投资价值。

核验记录与处理时间

来源原始时间字段:2026-11-17T21:15:34.000Z;日期依据:SEC accepted filing time (Atom and index checked); calendar date is America/New_York; not an inferred press-release time。

采集层首次发现:2026-11-17T21:30:30.518Z;事件路径观察:2026-11-17T21:30:58.617Z。

处理开始:2026-11-18T05:30:48.850Z;处理完成:2026-11-18T05:30:50.575Z;首次资格通过:2026-11-18T05:30:50.575Z;首次公开:2026-11-18T05:30:50.575Z。

公开模式:natural_new;处理方式:automatic;规则版本:sec_company_events_v3_filed_release;自然时槽:2026-11-18T05:30:23.513Z。

保留原始披露及首次时间,重新展示不重写发布时间。

公司身份依据 · OTC市场依据

身份核验记录:2026-11-18T05:30:49.617Z;来源核验记录:2026-11-18T05:30:49.617Z。